Scilex Holding Co
NASDAQ:SCLX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Lvji Technology Holdings Inc
HKEX:1745
|
CN |
|
Bellway PLC
LSE:BWY
|
UK |
|
Eastman Kodak Co
NYSE:KODK
|
US |
|
Y
|
Yinfu Gold Corp
OTC:ELRE
|
CN |
Scilex Holding Co
Stock-Based Compensation
Scilex Holding Co
Stock-Based Compensation Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Scilex Holding Co
NASDAQ:SCLX
|
Stock-Based Compensation
$14.6m
|
CAGR 3-Years
39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Stock-Based Compensation
$1.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Stock-Based Compensation
$553m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
9%
|
|
|
Pfizer Inc
NYSE:PFE
|
Stock-Based Compensation
$799m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
1%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Stock-Based Compensation
$820m
|
CAGR 3-Years
15%
|
CAGR 5-Years
13%
|
CAGR 10-Years
11%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Stock-Based Compensation
$626m
|
CAGR 3-Years
19%
|
CAGR 5-Years
15%
|
CAGR 10-Years
11%
|
|
Scilex Holding Co
Glance View
Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. The company is headquartered in Palo Alto, California and currently employs 2 full-time employees. The company went IPO on 2021-01-11. The firm's commercial product, ZTlido (lidocaine topical system) 1.8%, or ZTlido, is a prescription lidocaine topical product for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also commercializes Gloperba (colchicine USP) oral solution, a prophylactic treatment for painful gout flares in adults. The firm's three product candidates are SP-102 or SEMDEXA, a Phase 3, viscous gel formulation of a used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica; SP-103 5.4%, a Phase 2, triple-strength formulation of ZTlido, for the treatment of low back pain; and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule, for the treatment of chronic pain, fibromyalgia in multiple Phase 1 program.
See Also
What is Scilex Holding Co's Stock-Based Compensation?
Stock-Based Compensation
14.6m
USD
Based on the financial report for Dec 31, 2023, Scilex Holding Co's Stock-Based Compensation amounts to 14.6m USD.
What is Scilex Holding Co's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 3Y
39%
Over the last year, the Stock-Based Compensation growth was 177%. The average annual Stock-Based Compensation growth rates for Scilex Holding Co have been 39% over the past three years .
